title: Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b.
abstract: Spasticity is a disabling symptom of MS that is enhanced during interferon beta-lb (IFNbeta-1b) treatment. Nineteen patients with primary progressive MS were treated with IFNbeta-1b; an additional 19 patients did not receive this treatment. Thirteen of the 19 patients treated with IFNbeta-1b had increased spasticity requiring increased antispasticity drug administration. This observation suggests that further studies are needed before interferons can be so widely used in primary progressive MS patients.
authors.affiliation: Centro per lo Studio ed il Trattamento dei Neurolesi Lungodegenti, Cattedra di Neurofisiopatologia, University of Messina, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Bramanti
authors.forename: E
authors.initials: E
authors.lastname: Sessa
authors.forename: C
authors.initials: C
authors.lastname: Rifici
authors.forename: G
authors.initials: G
authors.lastname: D'Aleo
authors.forename: D
authors.initials: D
authors.lastname: Floridia
authors.forename: P
authors.initials: P
authors.lastname: Di Bella
authors.forename: F
authors.initials: F
authors.lastname: Lublin
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000009:adverse effects*; D000328:Adult; D018450:Disease Progression; D006801:Humans; D007167:Immunotherapy; D016899:Interferon-beta / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications / Q000628:therapy*; D009128:Muscle Spasticity / Q000139:chemically induced* / Q000209:etiology
chemical_list: D000276:Adjuvants, Immunologic; D016899:Interferon-beta